Stock Price Quote

SOLARA ACTIVE PHARMA SCIENCES LTD.

NSE : SOLARABSE : 541540ISIN CODE : INE624Z01016Industry : Pharmaceuticals & DrugsHouse : Private
BSE449.35-1.9 (-0.42 %)
PREV CLOSE ( ) 451.25
OPEN PRICE ( ) 456.85
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 2456
TODAY'S LOW / HIGH ( )444.35 461.65
52 WK LOW / HIGH ( )440.4 734.2
NSE449.800.25 (+0.06 %)
PREV CLOSE( ) 449.55
OPEN PRICE ( ) 449.65
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 78775
TODAY'S LOW / HIGH( ) 442.10 460.80
52 WK LOW / HIGH ( )440.2 734.4
BSE NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 23-02 2017
Management Info
R Ramakrishnan - Chairman Sandeep Rao - Managing Director
Registered Office

Address 9th Floor, ‘ Cyber One’, Unit No. 902,Plot No. 4 & 6, Sector 30 A,Vashi,
Navi Mumbai,
Maharashtra-400703

Phone 022 2789 2924 / 2789 3199

Email investors@solara.co.in

Website www.solara.co.in

Registrars Details
Cameo Corporate Services Ltd
Subramanian Buildings No 1 ,Club House Road,,Chennai
 Listing : BSE, NSE

NEWS

06Feb Solara Active Pharma Sciences informs
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosur..
17Dec Solara Active Pharma Sciences informs
Solara Active Pharma Sciences has informed that the Board of Directors o..
17Dec Solara Active Pharma Sciences informs
Solara Active Pharma Sciences has informed that the Board of Directors o..
17Dec Appointment of Director
Inter- alia, transacted and approved the appointment of Mr. Mohanraj S(D..
04Dec Clarification On Volume Movement
Clarification in relation to the mail received from exchange on December..
MORE

Financials

in Millions
QTR Dec 25 ANNUAL 25
Net Profit-174.2-10.8000000000006
Gross Profit -174.2 -10.8000000000006
Operating Profit 373.52129.8
Net Sales 349012837.6
MORE

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Alkem Laboratories (BSE)
peergroup  5619.05 (2.91%)
M.Cap ( in Cr)67184.17
Astrazeneca Pharma I (BSE)
peergroup  8801.65 (1.49%)
M.Cap ( in Cr)22004.13
Fredun Pharma (BSE)
peergroup  1690.95 (7.18%)
M.Cap ( in Cr)907.37
Glenmark Pharma (BSE)
peergroup  2228.25 (5.26%)
M.Cap ( in Cr)62881.40
NGL Fine-Chem (BSE)
peergroup  2355.35 (4.68%)
M.Cap ( in Cr)1455.14
MORE

Shareholding Pattern

NON-INSTITUTION 42.37%
PROMOTERS 42%
MUTUAL FUNDS/UTI 1.18%
FI/BANKS/INSURANCE 0.03%
GOVERNMENT 0%
FII 0%
MORE

About Solara Active Pharma Sciences Ltd.

Solara Active Pharma Sciences Ltd. was incorporated in the year 2017. Its today's share price is 449.35. Its current market capitalisation stands at Rs 2164.59 Cr. In the latest quarter, company has reported Gross Sales of Rs. 12837.6 Cr and Total Income of Rs.12929 Cr. The company's management includes Sandeep Rao, Kartheek Chintalapati Raju, Manish Gupta, Arun Kumar Pillai, Rajiv Vijay Nabar, Rajendra Kumar Srivastava, Kausalya Santhanam, R Ramakrishnan, Pooja Jaya Kumar.

It is listed on the BSE with a BSE Code of 541540 , NSE with an NSE Symbol of SOLARA and ISIN of INE624Z01016. It's Registered office is at 9th Floor, ‘ Cyber One’, Unit No. 902,Plot No. 4 & 6, Sector 30 A,VashiNavi Mumbai-400703, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells LLP

download beyond app
download beyond app
About Nirmal Bang About Nirmal Bang Awards & Accolades Careers at Nirmal Bang Contact Nirmal BangContact Dp Support Contact Trading Support
Product & Services Equity & Derivatives Trading Forex Trading Commodity Trading Institutional Broking Depository Services Algo Trading
Equity Price Analysis Volume Analysis Index Analysis News Analysis Corporate Action India Market Other Market Share Market Holidays T+1 Settlement securities
Derivatives Updates Market Report Overview
IPO IPO Issues Performance News & Analysis
Commodities Market Movers News & Commentary MCX / NCDEX HolidaysMCX Data feed product and Charges
Portfolio Management Service (PMS) NBSPL - PMS Disclosure Nirmal Bang PMS - Investor Charter SCORES complaints – February 2026 Online Grievance Portal – SCORES Online Dispute Resolution Portal – ODR Fee Calculator UPI ID - QR Code & Forms Contact Us
Mutual Funds About Nirmal Bang Wealth Why Associate with Nirmal Bang Mutual Fund Login Mutual Fund Register FAQs Mutual Fund Holidays SIP Calculator Mutual Funds Updates Mutual Funds Trends Mutual Fund Reports Mutual Fund Terms & Conditions Mutual Privacy Policy
NPS NPS Forms and Guidelines NPS-AML Policy
Nirmal Bang Research Technical Calls Equity Reports Commodity Reports Currency Research Institutional Research
Nirmal Bang Media Knowledge Center Blog Support Center Become A Partner Beyond Market Careers Sitemap Do's And Dont'sInvestor Complaint Data Important Update
Other Links Disclaimer Privacy Policy Policies and Procedures Terms Of Use Rules & Regulations Disclosures Risk Disclosure Grievances NPS Grievance Policy SEBI Scores RMS Policy Inspection SORM Policy - NBEPL CSR Committee CSR Policy
CSR Activities
FY-2020-2021 FY-2021-2022 FY-2022-2023 FY-2023-2024 FY-2024-2025
Investor Charter
Linked content_Investor Charter for Depositories and DPs Investor Charter for Depositories and DPs Investor Charter for Stock Broker RA NBEPL Investor Charter RA NBSPL Investor Charter Investor Complaints -RA Investor Complaints-NBEPL Investor NBCPL Investor NBEPL RA Investor NBSPL-RA
Evoting
NSDL Evoting CDSL Evoting
Compliance Annual report
NBSPL ACR Report Signed Annexure – NBSPL NBEPL ACR Report Signed Annexure – NBEPL
Client Bank Account list Smartodr Login Investor Grievance Flow Registered AP’s Surrendered List of AP’s KYC Activation Process Voluntary Freezing Blocking of Online Trading Account Internal Shortage Policy MCXCCL Client Reports Policy For GTC/GTD RBI Guidelines Transfer of Funds via SEBI-Validated UPI ID
Connect with Us
ATTENTION INVESTORS Depository IPO KYC Investor Guide
Inactive account treatment NBSPL Policy of AML NBEPL Policy of AMLNBSPL Policy of SurveillanceNBSPL CSR Policy Physical Settlement Policy of Derivative Aadhar UpdationNirmalbang Privacy Policy V1.0 Documents in Vernacular Languages NBSPL PMS Disclosure Document
Nirmal Bang Securities Pvt. Ltd. : Member NSE – ID 09391, SEBI Registration No. NSE CM Segment INZ000202536, Member NSE – ID 09391, SEBI Registration No. NSE FO Segment INZ000202536, Member NSE – ID 09391, SEBI Registration No. NSE CDS Segment INZ000202536, Member NSE Commodity – ID 09391, SEBI Registration No. NSE COMMODITY Segment Exchange Registered Broker, Member MSEI – ID 1067, SEBI Registration No. MSEI CM Segment INZ000202536, Member MSEI – ID 1067, SEBI Registration No. MSEI FO Segment INZ000202536, Member MSEI – ID 1067, SEBI Registration No. MSEI CDS Segment INZ000202536, Member MCX – ID 56460, SEBI Registration No. MCX COMMODITY Segment INZ000202536, Member NCDEX – ID 1268, SEBI Registration No. NCDEX COMMODITY Segment INZ000202536, Member ICEX – ID 2073, SEBI Registration No. ICEX COMMODITY Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE CM Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE FO Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE CDS Segment Exchange Registered Broker, Member BSE Commodity – ID 0498, SEBI Registration No. BSE COMMODITY Segment Exchange Registered Broker, SEBI Registration No. PMS INP000002981, SEBI Registration No. Research Analyst INP000002981, SEBI Registration No. DP Participants NSDL – CDSL IN-DP-CDSL 37-99,Member Comtrack Participant Id – ID 50274, Member NERL RP Id– ID R1447, Nirmal Bang Equities Private Limited Member BSE – ID 245, SEBI Registration No. BSE CM Segment INZ000186135, Member NSE – ID 13437, SEBI Registration No. BSE CM Segment INZ000186135, Member NSE – ID 13437, SEBI Registration No. NSE FO Segment INZ000186135, Member NSE Currency – ID 13437, SEBI Registration No. NSE CDS Segment INZ000186135, Member MSEI – ID 17780, SEBI Registration No. MSEI CM Segment INZ000186135, Member MSEI – ID 17780, SEBI Registration No. MSEI FO Segment INZ000186135, SEBI Registration No. Research Analyst Segment INH000001436, Nirmal Bang Commodities Private Limited Member MCX – ID 16590, SEBI Registration No. MCX COMMODITY Segment INZ000043630, Member NCDEX – ID 00362, SEBI Registration No. NCDEX COMMODITY Segment INZ000043630, Member ICEX – ID 1165, SEBI Registration No. ICEX COMMODITY Segment INZ000043630, Member NCDEX Spot Exchange – ID 10084,Comtrack Participant CPID -5040, Participant CDSL Commodity Repository Limited - 12013300
For Any Legal Department Grievances – Level 1, Please Get In Touch With Mr. Bhavin Pandya On 022-6273 9232 Or Write A Mail To bhavin.pandya@nirmalbang.com With Subject line As Grievances/Complaint.     |     For Any Legal Department Grievances – Level 2, Please Get In Touch With Mr. Kishor Kumar Agrawal On 022-6273 9252/9253 Or Write A Mail To kishorkumar.agrawal@nirmalbang.com With Subject line As Grievances/Complaint.     |     For Any Compliance Grievances / other grievances , Please Get In Touch With Mr. Samir Kamdar On 022-62739395/9396 Or Write A Mail To samir.kamdar@nirmalbang.com With Subject line As Grievances/Complaint.     |    
IMPORTANT LINKS: SEBI BSE NSE MCX CDSL NSDL NCDEX

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

AppleApp Store GooglePlay Store
AppleApp StoreGooglePlay Store
Support
Videos
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.